Nick Sireau
Chief Executive Officer & Co-Founder Serenatis Bio
Nick Sireau is a long-time patient advocate and social entrepreneur. He is Chair of Trustees of the AKU Society, a charity focused on finding treatments for Alkaptonuria, a rare disease affecting his two sons. He also founded Findacure (now Beacon), supporting rare disease patient groups, and Orchard OCD, which funds academic research into OCD, a common yet poorly treated and often devastating mental illness. He is CEO and Co-founder of Serenatis, a new biotech developing novel treatments for OCD. Nick holds a PhD in the Social Psychology of Collective Behaviour, is an Ashoka Fellow, and has edited key publications including Rare Diseases: Challenges and Opportunities for Social Entrepreneurs and The Patient Group Handbook.
Seminars
- Translating lived experience into actionable metrics that inform trial design and demonstrate patient-centered value
- Overcoming engagement barriers in rare disease and mental health, from stigma to delayed diagnosis, to improve recruitment and retention
- Implementing a ready-to-use checklist for embedding patient perspectives into everyday research decisions and regulatory interactions
